Tag Archive for: Calliditas Therapeutics

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

/in

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® (TARPEYO® (budesonide) delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy (IgAN). The Phase 3 trial met the primary endpoint, estimated glomerular filtration rate (eGFR), with Nefecon demonstrating significant kidney protective effect over […]

Read more

Raising awareness of Rare Disease

/in

Each year, Rare Disease Day aims to raise awareness of rare diseases and encourage positive change to patients’ lives. A disease is considered rare when it affects fewer than 1 in 2,000 people and there are 300 million people with rare diseases across the world.1 On Rare Disease Day 2023, we want to celebrate the […]

Read more

Monday, 28th February is #RareDiseaseDay

/in

We are proud to work with amazing companies focused on developing new treatments for rare diseases, generating change for the 300 million people worldwide

Read more

FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

/in

TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 TARPEYO (developed under the project name NEFECON) is the first and only FDA- approved treatment that was specifically designed for […]

Read more

Optimum Video Q&A: Getting to know Renee Aguiar-Lucander

/in

Since taking over as CEO of Calliditas Therapeutics in 2017, Renee Aguiar-Lucander has taken the biotech through an IPO in Stockholm and commenced a pivotal phase 3 trial plus major licensing deals and a secondary fund raise.  She has established a US presence, made transformational regulatory milestones, and this month completed a successful upsized US […]

Read more